LONDON, January 25, 2017 /PRNewswire/ --
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development
(Logo: http://photos.prnewswire.com/prnh/20151214/295722LOGO )
• 200 patients successfully recruited and randomised (dosed)
o 293 patients initially screened illustrating the demand from physicians for a new safe and effective treatment for Lupus
• 7 Countries and 28 sites are participating in the study
o US: 11 sites with 70 patients randomised
o Europe: 5 Countries and 16 sites with 81 patients randomised
o Mauritius: 1 site with 49 patients randomised
• Study status as at the end of January 2017
o over 80% of patients will have been treated for at least 3 months
o 2 patients have completed the study
o 24 patients will have been treated for 9 months
o 50 patients will have been treated for 6 months
o 90 patients will have been treated for 3 months
? • To date no drug (active or placebo) related 'Serious Adverse Events' have been reported. This is consistent with the strong safety profile of Lupuzor™ shown in its Phase IIb study
? • Top line results estimated to be reported in Q1 2018
Tim McCarthy, Chairman of ImmuPharma said: "We are delighted to now provide more details involved in the completion of recruitment of patients within our Lupuzor™ Phase III trial in Lupus.
293 patients were initially screened in this study. This illustrates the demand from physicians to meet the unmet medical need, for an effective and safe treatment for this debilitating and life threatening disease.
With the trial on track, two patients already safely completing their 12 month dosing regimen, we look forward to providing further updates on this pivotal Phase III trial as it progresses through 2017."
Dr. Robert Zimmer, President & Chief Scientific Officer added: "Thanks to the diligent work performed by Dr. Fanny Valleix, Head of Clinical Research at ImmuPharma in conjunction with Simbec-Orion, our contract research partner, we achieved our goal to complete patient recruitment before the end of 2016.
ImmuPharma plc (http://www.immupharma.org) Tim McCarthy, Chairman +44-(0)-20-7152-4080 Lisa Baderoon, Head of Investor Relations Twitter: @immupharma + 44-(0)-7721-413496
SOURCE Immupharma PLC
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All